U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H15N3.ClH
Molecular Weight 285.771
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EPINASTINE HYDROCHLORIDE

SMILES

Cl.NC1=NCC2N1C3=C(CC4=C2C=CC=C4)C=CC=C3

InChI

InChIKey=VKXSGUIOOQPGAF-UHFFFAOYSA-N
InChI=1S/C16H15N3.ClH/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16;/h1-8,15H,9-10H2,(H2,17,18);1H

HIDE SMILES / InChI

Description

Epinastine (brand names Alesion, Elestat, Purivist, Relestat) is a second-generation antihistamine and mast cell stabilizer. Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the α1-, α2-, and 5-HT2 –receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system. Elestat ophthalmic solution is indicated for the prevention of itching associated with allergic conjunctivitis.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
7.6 null [pIC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ELESTAT

Cmax

ValueDoseCo-administeredAnalytePopulation
0.042 ng/mL
0.05 % 2 times / day multiple, ocular
EPINASTINE plasma
Homo sapiens
0.025 ng/mL
0.05 % single, ocular
EPINASTINE plasma
Homo sapiens
14.82 ng/mL
20 mg single, oral
EPINASTINE plasma
Homo sapiens
15.69 ng/mL
20 mg 1 times / day steady-state, oral
EPINASTINE plasma
Homo sapiens
15.5 ng/mL
20.6 mg single, oral
EPINASTINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
0.347 ng × h/mL
0.05 % 2 times / day multiple, ocular
EPINASTINE plasma
Homo sapiens
0.465 ng × h/mL
0.05 % single, ocular
EPINASTINE plasma
Homo sapiens
144.88 ng × h/mL
20 mg single, oral
EPINASTINE plasma
Homo sapiens
157.38 ng × h/mL
20 mg 1 times / day steady-state, oral
EPINASTINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
11.9 h
0.05 % 2 times / day multiple, ocular
EPINASTINE plasma
Homo sapiens
9.26 h
0.05 % single, ocular
EPINASTINE plasma
Homo sapiens
7.08 h
20 mg single, oral
EPINASTINE plasma
Homo sapiens
7.35 h
20 mg 1 times / day steady-state, oral
EPINASTINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
35.8%
single, oral
EPINASTINE plasma
Homo sapiens

Doses

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dosage is one drop in each eye twice a day. Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent.
Route of Administration: Topical
In Vitro Use Guide
Nasal epithelial cells (NECs) were stimulated with 25 ng/ml TNF-alpha in the presence of Epinastine (10 to 30 ng/ml). The minimum concentration of Epinastine (EP) that caused a significant decrease in eosinophil survival was 25 ng/ml. The addition of EP into eosinophil cultures did not cause inhibition of eosinophil survival, which was prolonged by stimulation with granulocyte-macrophage colony-stimulating factor (GM-CSF), even when 40 ng/ml EP was added to cell cultures.